Preclinical evaluation of a new bombesin analog for imaging of gastrin-releasing peptide receptors

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 3, 2011, Pages 309-316

  Shirmardi, Seyed Pezhman ^a,b   Gandomkar, Mostafa ^b   Maragheh, Mohammad Ghannadi ^b   Shamsaei, Mojtaba ^a  

^a AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

^b Nuclear Sciences and Technology Research Institute   (Iran)

Author keywords

67Ga; bombesin; DOTA; GABA; PC 3 cells; tumor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMMONIUM ACETATE; BOMBESIN DERIVATIVE; DIAGNOSTIC AGENT; GALLIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BOMBESIN AMINE DERIVATIVE GA 67; GALLIUM 67; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CELL STRAIN; CELL STRAIN PC 3; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SCREENING; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOACTIVITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION, PRECLINICAL; GAMMA-AMINOBUTYRIC ACID; GASTRIN-RELEASING PEPTIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, CHEMICAL; NEOPLASMS; PEPTIDES; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79960053056     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2010.0912     Document Type: Article

References (41)

1. Plonowski A, Nagy A, Schally AV, et al. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. Int J Cancer 2000;88:652.
2. Karra SR, Schibli R, Gali H, et al. 99mTc labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconj Chem 1999;10:254.
3. Van deWiele C, Dumont F, van Belle S, et al Dierckx, is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging. Nucl Med Commun 2001; 22: 5.
4. Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides as autocrine growth factors in human small-cell lung cancer. Nature 1985;316:823.
5. Mahmoud S, Staley J, Taylor J, et al. Bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo. Cancer Res 1991;51:1798.
6. Preston SR, Woodhouse LF, Jones-Blackett GV, et al. Highaffinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa. Br J Cancer 1995;71:1097.
7. Zhang H, Chen J, Waldherr C, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium- 90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004;64:6707.
8. Smith CJ, Gali H, Sieckman GL, et al. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: An in vitro/ in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol 2003;30:101.
9. Breeman WA, Hofland LJ, de Jong M, et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 1999;81:658.
10. Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: A feasibility study. Eur J Nucl Med 2000;27:1694.
11. Smith CJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: A concise update. Nucl Med Biol 2003;30:861.
12. Hoffman TJ, Gali H,SmithCJ, et al.Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrinreleasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003;44:823.
13. Chen X, Park R, Hou Y, et al. microPET and autoradiographic imaging of GRP receptor expression with 64Cu- DOTA-[Lys3] bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004;45:1390.
14. Nock BA, Nikolopoulou A, Galanis A, et al. Potent bombesinlike peptides for GRP-receptor targeting of tumors with 99mTc: A preclinical study. J Med Chem 2005;48:100.
15. Baidoo KE, Lin KS, Zhan Y, et al. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem 1998;9:218.
16. Scopinaro F, De Vincentis G, Varvarigou AD, et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 2003; 30:1378.
17. La Bella R, Garcia-Garayoa E, Langer M, et al. In vitro and in vivo evaluation of a 99mTc (I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl Med Biol 2002;29:553.
18. Smith CJ, Sieckman GL, Owen NK, et al. Radiochemical investigations of gastrin-releasing peptide receptor-specific [99mTc (X)(CO)3-Dpr-Ser-Ser-Ser-Gln- Trp-Ala-Val-Gly-His- Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: Syntheses, radiolabeling, and in vitro/in vivo studies where Dpr2,3-diaminopropionic acid and XH2Oor P (CH2OH)3. Cancer Res 2003;63:4082.
19. Chen J, Nguyen H, Metcalfe E, et al. Formulation and in vitro metabolism studies with 177Lu-AMBA; a radiotherapeutic compound that targets gastrin releasing peptide receptors. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S281.
20. Nock B, Nikolopoulou A, Chiotellis E, et al. [99mTc] Demobesin 1, a novel potent bombesin analogue for GRP receptortargeted tumour imaging. Eur J Nucl Med Mol Imaging 2003;30:247.
21. Van de Wiele C, Dumont F, Dierckx RA, et al. Biodistribution and dosimetry of 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptorexpressing malignancies. J Nucl Med 2001;42:1722.
22. Schuhmacher J, Zhang H, Doll J, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. J Nucl Med 2005;46:691.
23. Rogers BE, Bigott HN, McCarthy DW, et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Culabeled bombesin analogue. Bioconjug Chem 2003;14:756.
24. Meyer GJ, Macke H, Schuhmacher H, et al. 68Ga -labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004;31:1097.
25. Breeman WA, De Jong M, Bernard BF, et al. Pre-clinical evaluation of [111In-DTPA-Pro1, Tyr4]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 1999;83:657.
26. Breeman WA, de Jong M, Erion JL, et al. Preclinical comparison of 111In -labeled DTPA or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 2002;43:1650.
27. Sadeghzadeh N, Gandomkar M, Najafi R, et al. Preparation and evaluation of a new 99mTc labeled bombesin derivative for tumor imaging. J Radioanal Nucl Chem 2010;283:181.
28. Sadeghzadeh N, Gandomkar M, Shafiee M, et al. Synthesis and evaluation of a new radiolabeled bombesin analogue for diagnosis of GRP receptor expressing tumors. Iran J Nucl Med 2009;17:18.
29. Gandomkar M, Najafi R, Shafiei M, et al. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]- octreotide as a new analogue in the detection of somatostatinreceptor- positive tumors. Nucl Med Biol 2007;34:651.
30. Gandomkar M, Najafi R, Shafiei M, et al. Clinical evaluation of antimicrobial peptide [99mTc/Tricine/HYNIC0] ubiquicidin 29-41 as a human-specific infection imaging agent. Nucl Med Biol 2009;36:199.
31. Hoffman TJ, Li N, Volkert WA, et al. Ochrymowcycz, synthesis and characterization of 105Rh labeled bombesin analogues: Enhancement of GRP receptor binding affinity utilizing aliphatic carbon chain linkers. J Label Compd Radiopharm 1997;40:490.
32. Hoffman TJ, Simpson SD, Smith CJ. Accumulation and retention of Tc-99m RP527 by GRP receptor expressing tumors in scid mice [abstract]. J Nucl Med 1999;40(suppl):104P.
33. Hoffman TJ, Smith CJ, and Simpson SD. Optimizing pharmacokinetics of 99mTc-GRP receptor targeting peptides using multi-amino acid linking groups [abstract]. J Nucl Med 2000;41(suppl):228P.
34. Zhang H, Schuhmacher J, Waser B, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumors. Eur J Nucl Med Mol Imaging 2007;34:1198.
35. de Visser M, Bernard HF, Erion JL, et al. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumors. Eur J Nucl Med Mol Imaging 2007;34:1228.
36. Garrison JC, Tammy LR, Sieckman GL, et al. Evaluation of the pharmacokinetic effects of various linking groups using the 111In-DOTA-X-BBN(7- 14)NH2 structural paradigm in a prostate cancer model. Bioconjug Chem 2008;19:1803.
37. Costantini DL, Hu M, Reilly R. Peptide motifs for insertion of radiolabeled biomolcules into cells and routing to the neucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm 2008;23:3.
38. Heppeler A, Froidevaux S, Macke HR, et al. Radiometallabeled macrocyclic chelator derivatised somatostatin analogue with superb tumor targeting properties and potential for receptor mediated internal radiotherapy. Chem Eur J 1999;5:1974.
39. Lantry LE, Cappelletti E, Maddalena ME, et al. 177Lu- AMBA: Synthesis and characterization of a selective 177Lulabeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006;47:1144.
40. Johnson CV, Shelton T, Smith CJ, et al. Evaluation of combined Lu-177-DOTA-8-AOC-BBN (7-14) NH2 GRP receptortargeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm 2006;21:155.
41. Antunes P, Ginj M, Zhang H, et al. Are radiogalliumlabelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982.